NAMS Stock Analysis: Buy, Sell, or Hold?
NAMS - NewAmsterdam Pharma Company N.V. Ordinary Shares
$27.79
-0.67 (-2.35%)
▼
5d:
-6.24%
30d:
-20.98%
90d:
-2.7%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Smart Money Distribution
None View Scanner →
Strength: 3.8/10
Get Alerted When NAMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NAMS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NAMS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NAMS is currently trading at $27.79, which is considered oversold relative to its 30-day fair value range of $29.63 to $34.93.
Technical Outlook: Technically, NAMS is showing sideways momentum. The price is currently testing key support at $26.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NAMS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $51.41 (+85.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NAMS is showing sideways momentum. The price is currently testing key support at $26.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NAMS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $51.41 (+85.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$29.63 -
$34.93
Company Quality Score
50/100
(HOLD)
Options IV Signal
30th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
Protect Your Profits
Holding NAMS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 30th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 85.0% below Wall St target ($51.41)
- CAUTION: Recommendation downgraded due to -6.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$29.63 -
$34.93
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$3.70
(13.3%)
Support & Resistance Levels
Support Level
$26.99
Resistance Level
$32.63
Current Trend
Sideways
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.14
Wall Street Target
$51.41
(+85.0%)
Revenue Growth (YoY)
2.1%
Share & Embed Analysis
Last updated: August 03, 2026 12:15 AM ET
Data refreshes hourly during market hours. Next update: 1:15 AM
Data refreshes hourly during market hours. Next update: 1:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Louis G Lange
SELL
44619 shares
2026-03-11
Johannes Jacob Piete Kas…
SELL
101409 shares
2026-03-09
Johannes Jacob Piete Kas…
SELL
94124 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 59 HOLD |
Advanced NAMS Option Strategies
Professional options setups generated by AI based on today's NAMS price and gamma walls.